Ishares Msci Spain ETF vs Zimmer Biomet Holdings Inc — how do they compare? Ishares Msci Spain ETF trades at $57.87 (market cap $2.30B), while Zimmer Biomet Holdings Inc trades at $89.19 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 7.4× Ishares Msci Spain ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Ishares Msci Spain ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Spain ETF for 41 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| EWP | ZBH | |
|---|---|---|
Market Cap | $2.30B | $16.95B |
Volume | 845,747 | 2,505,240 |
Sector | Broad Market / Factor | Health |
52-Week High | $63.23 | $103.98 |
52-Week Low | $48.33 | $79.58 |
Typical Hold Time | 41 Days | 89 Days |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Signals from Pluang's Aura AI — not financial advice
EWP, the iShares MSCI Spain ETF, trades at $57.82, down 1.73% on the day amid a bearish technical signal. The ETF offers concentrated exposure to Spanish equities with a discounted 16x P/E and 2.7% yield, heavily weighted in financials and utilities. Recent ECB rate hikes to 2.5% and energy-driven inflation pressures create macroeconomic headwinds for European markets.
While EWP provides attractive valuation and yield, the bearish technical outlook and ECB tightening cycle present near-term challenges. The concentrated portfolio in Spanish banks and utilities offers stability but limits diversification. Upside potential depends on Spain's economic resilience amid broader eurozone pressures.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →